Mentari Therapeutics, Inc. (MTRI) Stock Price & Analysis

Mentari Therapeutics, Inc. (MTRI) is trading at USD 15.11, down 13.48% today, as of November 18, 2026 at 20:48 UTC (US market open; quotes may be delayed), according to Nexqual market data.

MTRI last closed at USD 17.5; today's session has ranged USD 14.78–18.12 on volume of 214,194 shares. Market capitalization is $880.84M, with a 52-week range of USD 5.75–23.3 (NCM). Source: Nexqual, retrieved November 18, 2026 at 20:53 UTC.

Also available as compact Markdown for AI agents: nexqual.com/MTRI.md

Key facts (MTRI)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MTRI)

USDFY2022FY2023FY2024FY2025FY2026TTM
Revenue$1.4M$4.1M$4.6M$4.9M——
Gross profit$544K$1.4M$1.1M$1.7M——
Operating income-$18.6M-$7.9M————
Net income-$18.6M-$7.9M-$7.7M-$8.2M-$12.6M-$13.2M
EPS (diluted)-$6634.00-$650.00-$201.40-$83.60-$31.20—
Free cash flow-$15.6M-$7.4M-$7.0M———
Gross margin39.8%33.9%23.9%34.5%——
Operating margin-1361.9%-192.2%————
Net margin-1361.9%-192.2%-166.9%-165.1%——
Revenue growth-28.3%+202.8%+11.2%+7.5%——
Cash + short-term investments$6.2M$9.0M$6.6M$11.1M$2.2M—

Fiscal years end Jun. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (MTRI)

Earnings yield -1.49%

Insider purchases (SEC Form 4, open-market, last ~7 months) (MTRI)

12 purchases, $1.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Trade dateInsiderRoleSharesValueAvg priceInsider type
2026-11-05Adar1 Capital Management, Llc2,640$35K13.1Too little history (no open-market trades in 2023–2025)
2026-10-23Adar1 Capital Management, Llc4$0K1.32Too little history (no open-market trades in 2023–2025)
2026-10-16…2026-10-19Adar1 Capital Management, Llc1,087$1K1.32Too little history (no open-market trades in 2023–2025)
2026-10-13…2026-10-15Adar1 Capital Management, Llc9,569$13K1.33Too little history (no open-market trades in 2023–2025)
2026-10-06…2026-10-08Adar1 Capital Management, Llc10,903$14K1.33Too little history (no open-market trades in 2023–2025)
2026-10-01…2026-10-05Adar1 Capital Management, Llc42,920$57K1.33Too little history (no open-market trades in 2023–2025)
2026-09-14…2026-09-16Adar1 Capital Management, Llc91,101$118K1.3Too little history (no open-market trades in 2023–2025)
2026-07-14…2026-07-16Vivo Opportunity, Llc20,546$32K1.55Too little history (no open-market trades in 2023–2025)
2026-07-15Adar1 Capital Management, Llc1,000$2K1.55Too little history (no open-market trades in 2023–2025)
2026-06-30…2026-07-02Vivo Opportunity, Llc6,551$10K1.55Too little history (no open-market trades in 2023–2025)
2026-05-20…2026-06-08Vivo Opportunity, Llc249,227$392K1.57Too little history (no open-market trades in 2023–2025)
2026-05-19Adar1 Capital Management, Llc468,551$722K1.54Too little history (no open-market trades in 2023–2025)

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (MTRI)

Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 33 (low 33, high 33).

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-11-10JefferiesInitiatedBuy$30
2026-11-10StifelInitiatedBuy$30

Total return (dividends reinvested) (MTRI)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return+3.5%-99.8%
S&P 500 (SPY)+11.9%+66.7%
Per year+3.5%-72.1%
Volatility (annualized)124.3%117.1%
Max drawdown-57.9% (Nov 2025→Mar 2026)-99.9% (Nov 2021→May 2026)

Dividends (MTRI)

MTRI paid no cash dividend in the last five years.

MTRI major shareholder filing: Schedule 13D, Nov 12, 2026

Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Evan Harwin filed a Schedule 13D with the SEC on Nov 12, 2026, reporting up to 19.99% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:

The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of November 6, 2026. The Reporting Persons' securities include 10,555,507 shares of Common Stock directly held by Fund II, and exclude (i) 4,013,000 shares of Common Stock issuable upon conversion of 4,013 shares of Series A Preferred Stock directly held by Fund II and (ii) 1,468,222 shares of Common Stock issuable upon exercise of Pre-Funded Warrants directly held by Fund II. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock and the conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock. The securities exclude shares of Common Stock issuable upon exercise of Pre-Funded Warrants and conversion of Series A Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the outstanding shares of Common Stock, the beneficial ownership limitation with respect to the Series A Preferred Stock will automatically reduce to 9.99%. …

Source: SEC EDGAR, Schedule 13D filed Nov 12, 2026. Quoted word for word; Nexqual adds no interpretation.

MTRI recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 16, 2026Schedule 13G/ASquadron Master Fund LP, Squadron Capital Management LLC: 0.0% of shares, passive 5%+ holder (amended)
Nov 16, 20268-KCompleted an acquisition or sale of assets; Quarterly results
“Financial Information Unaudited Financial Statements The unaudited condensed consolidated financial statements of Mentari as of September 30, 2026 and for the three and nine months ended September 30, 2026 and related notes thereto are attached hereto as Exhibit 99.1 and incorporated herein by reference. Management's Discussion and Analysis of Financial Condition and Results of Operations Mentari's Management's Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months…”
Nov 13, 2026Schedule 13GCommodore Capital LP, Commodore Capital Master LP: 5.6% of shares, passive 5%+ holder
Nov 13, 2026Schedule 13GDeep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd.: 5.6% of shares, passive 5%+ holder
Nov 12, 2026Schedule 13DFairmount Funds Management LLC, Fairmount Healthcare Fund II L.P.: 20.0% of shares, 5%+ holder that may seek to influence the company
“The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of November 6, 2026. The Reporting Persons' securities include 10,555,507 shares of Common Stock directly held by Fund II, and exclude (i) 4,013,000 shares…”
Nov 10, 20268-KEntered a material agreement; Completed an acquisition or sale of assets; Quarterly results; Unregistered sale of shares; Change to shareholder rights; Change in control; Director or executive officer change, or pay arrangement; Bylaws or fiscal-year change; Code of ethics change or waiver; Item 5.06
“The information set forth under the headings " Contingent Value Rights Agreement " and " Registration Rights Agreement " in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 1.01. Indemnification Agreements On November 6, 2026, the Company entered into indemnification agreements with each of its directors and executive officers (collectively, the " Indemnitees ," and such agreements, the " Indemnification Agreements "), which replaced and superseded any previous…”
Nov 9, 20268-KRegulation FD disclosure
Nov 5, 20268-KRegulation FD disclosure
Nov 5, 20268-KBylaws or fiscal-year change; Shareholder vote results; Other material event
“On November 4, 2026, the Company held its Shareholders Meeting, at which the proposals set forth below, relating to the Merger Agreement and other matters, were submitted to the Company's shareholders. The proposals are described in detail in the Company's proxy statement/prospectus, dated October 1, 2026 and included as part of the Company's registration statement on Form S-4 (File No. 333-297234) (the "Proxy Statement"). There were 5,493,735 Common Shares outstanding and entitled to vote on September 25, 2026,…”
Nov 3, 20268-KRegulation FD disclosure
Nov 3, 202610-QQuarterly report · period ended Sep 30, 2026
Nov 2, 2026425Merger or acquisition communication
Oct 27, 2026425Merger or acquisition communication
Oct 7, 2026Schedule 13G/AADAR1 Capital Management, LLC, Daniel Schneeberger: 17.2% of shares, passive 5%+ holder (amended)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

MTRI suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
CustomerBayMedica“Since our inception, we have generated revenue from BayMedica product sales and no sales from any other sources and have incurred significant operating losses and negative cash flows from our operations.”

Quoted from the company's 10-K filed Sep 9, 2026.

MTRI company outlook (results filed Nov 16, 2026)

Quoted word-for-word from the SEC 8-K results press release.

MTRI analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter———$0—
Next quarter———$0—
Current fiscal year (ends Jun 2027)$-1.75$0.00−$1.75$01
Next fiscal year———$0—

Key Statistics (as of November 18, 2026 at 20:53 UTC)

PriceUSD 15.11
Change▼ 13.48% (down)
Previous CloseUSD 17.5
OpenUSD 18.12
Day RangeUSD 14.78 – 18.12
52-Week RangeUSD 5.75 – 23.3
Volume214,194 shares
Market Cap$880.84M
ExchangeNCM

Technical Analysis (MTRI)

Nexqual's technical model rates MTRI "NEUTRAL" based on 2 bullish and 3 bearish signals across 129 daily candles, as of November 18, 2026 at 20:53 UTC.

Overall SignalNEUTRAL
RSI (14)48.49 (neutral)
vs SMA50Above (USD 14.47)
MACD0.78 (positive)

Analyst Ratings (MTRI)

Wall Street analysts rate MTRI "Buy" based on 2 analysts, with a mean price target of USD 33 (range USD 33–33), per Nexqual as of November 18, 2026 at 20:53 UTC.

Consensus RatingBuy
Analyst Count2
Mean TargetUSD 33
High TargetUSD 33
Low TargetUSD 33
Buy / Hold / Sell2 / 0 / 0

Earnings (MTRI)

Next Earnings Date2027-02-10

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Financials & Fundamentals (MTRI)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Financial Health Score (MTRI)

Nexqual rates Mentari Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 20:53 UTC.

GrowthMixed — No data
ProfitabilityWeak — Gross margin 0%, operating 0% (last 12 months)
Balance SheetMixed — No data
Cash FlowWeak — Operating cash flow -$9M (FY ended Jun 2026, 10-K)
EfficiencyCritical — ROE not meaningful (negative equity); ROA -1008.1% (last 4 quarters, SEC)

Ownership (MTRI)

Insider Ownership+0.12%
Institutional Ownership+27.10%
Shares Outstanding58.30M

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Leadership (MTRI)

Mentari Therapeutics, Inc. is led by Gregory J. Divis, CEO & Director, per Nexqual as of November 18, 2026 at 20:53 UTC.

CEO & DirectorGregory J. Divis

From Mentari Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-09-09)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
BLTEBelite Bio, IncUSD 156.45▼ 0.81%
KODKodiak Sciences IncUSD 97.7▲ 0.93%
ORKAOruka Therapeutics, Inc.USD 95.68▼ 0.67%
IMVTImmunovant, Inc.USD 33.24▲ 0.08%
AXSMAxsome Therapeutics, Inc.USD 133.89▼ 1.52%
IBRXImmunityBio, Inc.USD 6.7▲ 6.95%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt